CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: EIF2AK2 (ImmuneEditome ID:5610)

1. Gene summary of enriched editing regions for EIF2AK2

check button Gene summary
Gene informationGene symbol

EIF2AK2

Gene ID

5610

GeneSynonymsDYT33|EIF2AK1|LEUDEN|PKR|PPP1R83|PRKR
GeneCytomap

2p22.2

GeneTypeprotein-coding
GeneDescriptioninterferon-induced, double-stranded RNA-activated protein kinase|P1/eIF-2A protein kinase|double stranded RNA activated protein kinase|eIF-2A protein kinase 2|interferon-inducible elF2alpha kinase|p68 kinase|protein kinase R|protein kinase RNA-regulated|protein kinase, interferon-inducible double stranded RNA dependent|protein phosphatase 1, regulatory subunit 83|tyrosine-protein kinase EIF2AK2
GeneModificationdate20230518
UniprotIDP19525;A0A7P0TAL9;A0A7P0TBA9;A0A7P0Z4M0
PubMed ID

33588244

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr2:37100421-37104937:-ENST00000233057.7ENSG00000055332.15EIF2AK2UTR3MER45A,L1MC4,(AT)n,AluJr4,AluJo,AluSq2,L1MC5a,(ATAC)n,(TG)n,L2c,MLT1D,AluSx1chr2:37100421-37104937:-.alignment
chr2:37115110-37116083:-ENST00000233057.7ENSG00000055332.15EIF2AK2intronicL3,AluSz,(T)n,AluYchr2:37115110-37116083:-.alignment
chr2:37115110-37116083:-ENST00000395127.5ENSG00000055332.15EIF2AK2intronicL3,AluSz,(T)n,AluYchr2:37115110-37116083:-.alignment
chr2:37115110-37116083:-ENST00000405334.4ENSG00000055332.15EIF2AK2intronicL3,AluSz,(T)n,AluYchr2:37115110-37116083:-.alignment
chr2:37153364-37153806:-ENST00000233057.7ENSG00000055332.15EIF2AK2intronicAluJr,L1MB4chr2:37153364-37153806:-.alignment
chr2:37153364-37153806:-ENST00000390013.3ENSG00000055332.15EIF2AK2intronicAluJr,L1MB4chr2:37153364-37153806:-.alignment
chr2:37153364-37153806:-ENST00000395127.5ENSG00000055332.15EIF2AK2intronicAluJr,L1MB4chr2:37153364-37153806:-.alignment
chr2:37153364-37153806:-ENST00000411537.5ENSG00000055332.15EIF2AK2intronicAluJr,L1MB4chr2:37153364-37153806:-.alignment


Top

2. Tumor-specific enriched editing regions for EIF2AK2


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr2:37100421-37104937:-BRCAEER8.9901e-30image
ENSG00000055332.15,EIF2AK2BRCAEAG9.4737e-30image
chr2:37100421-37104937:-COADEER3.9400e-10image
ENSG00000055332.15,EIF2AK2COADEAG3.8265e-10image
chr2:37100421-37104937:-HNSCEER1.5134e-04image
ENSG00000055332.15,EIF2AK2HNSCEAG1.5252e-04image
chr2:37100421-37104937:-KICHEER1.5366e-08image
ENSG00000055332.15,EIF2AK2KICHEAG1.5366e-08image
chr2:37100421-37104937:-KIRCEER3.4946e-11image
ENSG00000055332.15,EIF2AK2KIRCEAG3.4879e-11image
chr2:37100421-37104937:-LIHCEER2.9779e-02image
ENSG00000055332.15,EIF2AK2LIHCEAG2.9622e-02image
chr2:37100421-37104937:-THCAEER4.2569e-06image
ENSG00000055332.15,EIF2AK2THCAEAG4.3271e-06image
chr2:37100421-37104937:-UCECEER1.2589e-08image
ENSG00000055332.15,EIF2AK2UCECEAG1.3649e-08image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
ENSG00000055332.15,EIF2AK2BLCAPathEAG2.0228e-021.3696e-020.1247image
chr2:37100421-37104937:-BLCAPathEER1.7782e-021.2208e-020.1268image
ENSG00000055332.15,EIF2AK2KIRCPathEAG2.3493e-051.4335e-050.1881image
chr2:37100421-37104937:-KIRCPathEER2.3657e-051.4421e-050.1880image
ENSG00000055332.15,EIF2AK2KIRPPathEAG1.0501e-022.2235e-020.1463image
chr2:37100421-37104937:-KIRPPathEER3.3391e-031.1288e-020.1620image
ENSG00000055332.15,EIF2AK2THCAPathEAG7.5108e-041.6025e-030.1425image
chr2:37100421-37104937:-THCAPathEER7.4034e-041.5616e-030.1428image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for EIF2AK2


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr2:37100421-37104937:-BLCAEERENSG00000268087,CTC-429P9.2-0.47262.3293e-192.9505e-22-0.4649imageNADAR;DGCR8;EIF4A3;ELAVL1;NOP56;U2AF2NAT_cells_CD4_memory_activatedGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chr2:37100421-37104937:-BLCAEERENSG00000178761,FAM219B-0.43104.4486e-162.7630e-17-0.4110imageNADAR;CELF2;DGCR8;EIF4A3;ELAVL1;ELAVL3;GNL3;HNRNPC;IGF2BP2;NOP56;NOP58;RBFOX2;U2AF2NAMacrophages_M1GSVA_HALLMARK_COMPLEMENT
chr2:37100421-37104937:-BLCAEERENSG00000100426,ZBED4-0.42492.8126e-154.2486e-17-0.4087imageNADAR;CELF2;DGCR8;DHX9;EIF4A3;ELAVL1;ELAVL3;GNL3;HNRNPC;IGF2BP2;NOP56;NOP58;RBFOX2;U2AF2NAMast_cells_activatedGSVA_HALLMARK_COAGULATION
chr2:37100421-37104937:-BLCAEERENSG00000100393,EP300-0.42453.6293e-159.4244e-18-0.4165imageNADAR;CELF2;DGCR8;DHX9;EIF4A3;ELAVL1;ELAVL3;GNL3;HNRNPC;IGF2BP2;NOP56;NOP58;RBFOX2;U2AF2EP300T_cells_CD4_memory_activatedGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chr2:37100421-37104937:-BLCAEERENSG00000167548,KMT2D-0.40764.7325e-148.0046e-17-0.4054imageNADAR;CELF2;DGCR8;DHX9;EIF4A3;ELAVL1;ELAVL3;GNL3;HNRNPC;IGF2BP2;NOP56;NOP58;RBFOX2;U2AF2NADendritic_cells_activatedGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chr2:37100421-37104937:-BLCAEERENSG00000140382,HMG20A-0.40806.0982e-143.9879e-17-0.4091imageNADAR;CELF2;DGCR8;DHX9;EIF4A3;ELAVL1;ELAVL3;GNL3;HNRNPC;IGF2BP2;NOP56;NOP58;RBFOX2;U2AF2NAT_cells_CD4_memory_restingGSVA_HALLMARK_PROTEIN_SECRETION
chr2:37100421-37104937:-BLCAEERENSG00000140992,PDPK1-0.40061.6782e-135.1813e-18-0.4195imageNADAR;CELF2;DGCR8;DHX9;EIF4A3;ELAVL1;ELAVL3;GNL3;HNRNPC;IGF2BP2;NOP56;NOP58;RBFOX2;U2AF2NAT_cells_CD4_memory_restingGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chr2:37100421-37104937:-BLCAEERENSG00000101191,DIDO1-0.39128.8222e-131.1069e-16-0.4037imageNADAR;CELF2;DGCR8;DHX9;EIF4A3;ELAVL1;ELAVL3;GNL3;HNRNPC;IGF2BP2;NOP56;NOP58;RBFOX2;U2AF2DIDO1T_cells_CD4_memory_activatedGSVA_HALLMARK_COAGULATION
chr2:37100421-37104937:-LIHCEERENSG00000135966,TGFBRAP1-0.42504.6094e-128.0173e-14-0.4032imageNADAR;CELF2;DGCR8;DHX9;EIF4A3;ELAVL1;ELAVL3;GNL3;HNRNPC;IGF2BP2;NOP56;NOP58;RBFOX2;U2AF2TGFBRAP1Macrophages_M0GSVA_HALLMARK_MITOTIC_SPINDLE
chr2:37100421-37104937:-LIHCEERENSG00000075539,FRYL-0.43024.7583e-125.2373e-14-0.4060imageNADAR;CELF2;DGCR8;DHX9;EIF4A3;ELAVL1;ELAVL3;GNL3;HNRNPC;IGF2BP2;NOP56;NOP58;RBFOX2;U2AF2NADendritic_cells_restingGSVA_HALLMARK_MITOTIC_SPINDLE

More results



Top

4. Enriched editing regions and immune related splicing for EIF2AK2


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000055332.15,EIF2AK2
BLCAEAGIRENSG00000128309.12chr2237024191:37024810:37026998:37027053-0.31252.7512e-091.5301e-13-0.4080imageNADAR;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;EIF4A3;ELAVL1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;ZNF184NAT_cells_CD4_naiveGSVA_HALLMARK_UV_RESPONSE_UP
ENSG00000055332.15,EIF2AK2
BLCAEAGIRENSG00000168672.3chr8126552814:126553503:126556264:126556271-0.33922.7804e-096.8084e-16-0.4072imageNADAR;ALYREF;BCCIP;CELF2;CSTF2T;DDX54;DGCR8;EIF4A3;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR2;HNRNPA1;HNRNPC;HNRNPD;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS2;LIN28;LIN28A;LIN28B;MBNL2;MOV10;NUMA1;PCBP2;PRPF8;RANGAP1;RBFOX2;RBM47;RNF219;SRSF1;SRSF3;TIA1;TIAL1;U2AF2;UPF1;YTHDC1;ZC3H7B;ZNF184NAT_cells_CD4_memory_restingGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY
chr2:37100421-37104937:-
BLCAEERIRENSG00000112081.12chr636598848:36598983:36599820:36600276-0.37286.2921e-111.8025e-16-0.4026imageNADAR;CELF2;DGCR8;DHX9;EIF4A3;ELAVL1;ELAVL3;GNL3;HNRNPC;IGF2BP2;NOP56;NOP58;RBFOX2;U2AF2NADendritic_cells_activatedGSVA_HALLMARK_UV_RESPONSE_UP
chr2:37100421-37104937:-
BLCAEERIRENSG00000130175.5chr1911449265:11449882:11450428:11450716-0.55762.4055e-261.0192e-32-0.5549imageNADAR;DGCR8;DHX9;EIF4A3;ELAVL1;ELAVL3;GNL3;HNRNPC;IGF2BP2;NOP56;NOP58;RBFOX2;U2AF2PRKCSHMacrophages_M1GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
ENSG00000055332.15,EIF2AK2
BLCAEAGESENSG00000198492.10chr128738258:28738338:28742402:28743986:28768928:28769125-0.34584.2753e-091.0175e-17-0.4181imageNACIN1;ADAR;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM27;RBM47;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;ZC3H7B;ZNF184YTHDF2Dendritic_cells_activatedGSVA_HALLMARK_MITOTIC_SPINDLE
ENSG00000055332.15,EIF2AK2
BLCAEAGIRENSG00000205581.6chr2139345145:39347483:39348291:39348339-0.31598.5069e-091.4505e-14-0.4010imageNACIN1;ADAR;ALYREF;AUH;BCCIP;BUD13;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM27;RBM47;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;ZC3H7B;ZNF184NAT_cells_CD4_memory_activatedGSVA_HALLMARK_UV_RESPONSE_UP
chr2:37100421-37104937:-
BLCAEERIRENSG00000163608.10chr3113011044:113012811:113013271:113013361-0.33601.3557e-101.3946e-14-0.4040imageNADAR;CELF2;DGCR8;DHX9;EIF4A3;ELAVL1;ELAVL3;GNL3;HNRNPC;IGF2BP2;NOP56;NOP58;RBFOX2;U2AF2NAT_cells_CD4_naiveGSVA_HALLMARK_UV_RESPONSE_UP
ENSG00000055332.15,EIF2AK2
BLCAEAGIRENSG00000104529.13chr8143588990:143590081:143590607:143590729-0.29182.0051e-089.6379e-14-0.4130imageNACIN1;ADAR;ALYREF;AUH;BCCIP;BUD13;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;ELAVL1;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM27;RBM47;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;ZC3H7B;ZNF184NAMacrophages_M1GSVA_HALLMARK_UV_RESPONSE_UP
ENSG00000055332.15,EIF2AK2
BLCAEAGIRENSG00000136527.13chr3185925084:185926734:185931576:185931618-0.29866.1702e-086.2793e-17-0.4257imageNACIN1;ADAR;ALYREF;AUH;BCCIP;BUD13;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM27;RBM47;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;ZC3H7B;ZNF184NAT_cells_CD4_naiveGSVA_HALLMARK_UV_RESPONSE_UP
chr2:37100421-37104937:-
BLCAEERIRENSG00000168672.3chr8126552814:126553503:126556264:126556271-0.33891.9998e-097.3099e-16-0.4068imageNADAR;CELF2;DGCR8;EIF4A3;ELAVL1;ELAVL3;HNRNPC;IGF2BP2;RBFOX2;U2AF2NAT_cells_CD4_memory_restingGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAY

More results



Top

5. Enriched editing regions and immune infiltration for EIF2AK2


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr2:37100421-37104937:-ACCEERDendritic_cells_activated4.1990e-02-0.2511image
ENSG00000055332.15,EIF2AK2ACCEAGDendritic_cells_activated4.1990e-02-0.2511image
chr2:37100421-37104937:-BLCAEERMacrophages_M11.1017e-070.2652image
ENSG00000055332.15,EIF2AK2BLCAEAGMacrophages_M11.0988e-070.2652image
chr2:37100421-37104937:-BRCAEERNK_cells_activated5.6807e-130.2176image
ENSG00000055332.15,EIF2AK2BRCAEAGNK_cells_activated7.0258e-130.2167image
chr2:37100421-37104937:-CESCEERMacrophages_M08.9589e-05-0.2246image
ENSG00000055332.15,EIF2AK2CESCEAGMacrophages_M09.1861e-05-0.2242image
chr2:37100421-37104937:-CHOLEERNK_cells_resting3.5084e-02-0.3626image
ENSG00000055332.15,EIF2AK2CHOLEAGNK_cells_resting3.5084e-02-0.3626image
chr2:37100421-37104937:-COADEERMacrophages_M13.6152e-030.1746image
ENSG00000055332.15,EIF2AK2COADEAGMacrophages_M13.3520e-030.1760image
chr2:37100421-37104937:-DLBCEERB_cells_naive3.4761e-03-0.4940image
ENSG00000055332.15,EIF2AK2DLBCEAGB_cells_naive1.6360e-02-0.4149image
chr2:37100421-37104937:-ESCAEERT_cells_regulatory_(Tregs)3.5754e-04-0.2779image
ENSG00000055332.15,EIF2AK2ESCAEAGT_cells_regulatory_(Tregs)3.6279e-04-0.2776image
chr2:37100421-37104937:-GBMEERMacrophages_M02.8405e-07-0.3848image
ENSG00000055332.15,EIF2AK2GBMEAGMacrophages_M02.8405e-07-0.3848image
chr2:37100421-37104937:-HNSCEERT_cells_CD4_memory_resting1.0262e-03-0.1486image
ENSG00000055332.15,EIF2AK2HNSCEAGT_cells_CD4_memory_resting1.0100e-03-0.1488image
chr2:37100421-37104937:-KICHEERB_cells_naive9.3021e-03-0.3304image
ENSG00000055332.15,EIF2AK2KICHEAGB_cells_naive9.3021e-03-0.3304image
chr2:37100421-37104937:-KIRCEERT_cells_CD89.5436e-080.2692image
ENSG00000055332.15,EIF2AK2KIRCEAGT_cells_CD89.2767e-080.2694image
chr2:37100421-37104937:-KIRPEERT_cells_regulatory_(Tregs)4.6712e-060.2741image
ENSG00000055332.15,EIF2AK2KIRPEAGT_cells_regulatory_(Tregs)2.4533e-060.2817image
chr2:37100421-37104937:-LAMLEERT_cells_CD4_memory_activated3.0028e-030.2407image
ENSG00000055332.15,EIF2AK2LAMLEAGT_cells_CD4_memory_activated2.3790e-030.2463image
chr2:37100421-37104937:-LGGEERMacrophages_M02.7548e-05-0.1817image
ENSG00000055332.15,EIF2AK2LGGEAGMacrophages_M02.7548e-05-0.1817image
chr2:37100421-37104937:-LUADEERT_cells_gamma_delta4.9880e-130.3106image
ENSG00000055332.15,EIF2AK2LUADEAGT_cells_gamma_delta4.7804e-130.3109image
chr2:37100421-37104937:-LUSCEERT_cells_CD4_memory_activated3.0208e-110.2920image
ENSG00000055332.15,EIF2AK2LUSCEAGT_cells_CD4_memory_activated3.0208e-110.2920image
chr2:37100421-37104937:-MESOEERMacrophages_M21.4023e-02-0.2704image
ENSG00000055332.15,EIF2AK2MESOEAGMacrophages_M21.4023e-02-0.2704image
chr2:37100421-37104937:-OVEERT_cells_CD83.5587e-060.2675image
ENSG00000055332.15,EIF2AK2OVEAGT_cells_CD83.8939e-060.2664image
chr2:37100421-37104937:-PAADEERT_cells_follicular_helper5.4951e-030.2085image
ENSG00000055332.15,EIF2AK2PAADEAGT_cells_follicular_helper5.4951e-030.2085image
chr2:37100421-37104937:-PCPGEERNK_cells_resting2.9427e-030.2255image
ENSG00000055332.15,EIF2AK2PCPGEAGNK_cells_resting2.9521e-030.2254image
chr2:37100421-37104937:-PRADEERT_cells_CD85.3564e-050.1820image
ENSG00000055332.15,EIF2AK2PRADEAGT_cells_CD88.5067e-050.1771image
chr2:37100421-37104937:-READEERT_cells_CD4_memory_activated2.8230e-04-0.3645image
ENSG00000055332.15,EIF2AK2READEAGT_cells_CD4_memory_activated2.8230e-04-0.3645image
chr2:37100421-37104937:-SARCEERMacrophages_M11.9184e-030.1965image
ENSG00000055332.15,EIF2AK2SARCEAGMacrophages_M12.0025e-030.1953image
chr2:37100421-37104937:-SKCMEERT_cells_CD81.5667e-130.3365image
ENSG00000055332.15,EIF2AK2SKCMEAGT_cells_CD81.5669e-130.3365image
chr2:37100421-37104937:-STADEERMacrophages_M18.8683e-050.2026image
ENSG00000055332.15,EIF2AK2STADEAGMacrophages_M15.9316e-050.2075image
chr2:37100421-37104937:-TGCTEERMacrophages_M21.4236e-07-0.4216image
ENSG00000055332.15,EIF2AK2TGCTEAGMacrophages_M21.4236e-07-0.4216image
chr2:37100421-37104937:-THCAEERT_cells_regulatory_(Tregs)3.5779e-050.1858image
ENSG00000055332.15,EIF2AK2THCAEAGT_cells_regulatory_(Tregs)3.8600e-050.1850image
chr2:37100421-37104937:-THYMEERMacrophages_M11.5445e-030.3141image
ENSG00000055332.15,EIF2AK2THYMEAGMacrophages_M11.6759e-030.3119image
chr2:37100421-37104937:-UCECEERT_cells_CD81.8892e-020.1815image
ENSG00000055332.15,EIF2AK2UCECEAGT_cells_CD81.7085e-020.1844image
chr2:37100421-37104937:-UCSEERB_cells_naive8.5396e-03-0.3545image
ENSG00000055332.15,EIF2AK2UCSEAGB_cells_naive8.5736e-03-0.3543image
chr2:37100421-37104937:-UVMEERT_cells_regulatory_(Tregs)3.1320e-040.4332image
ENSG00000055332.15,EIF2AK2UVMEAGT_cells_regulatory_(Tregs)3.1320e-040.4332image


Top

6. Enriched editing regions and immune gene sets for EIF2AK2


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot
chr2:37100421-37104937:-BRCAEER2.2129e-04image4.3228e-03-0.0870image
ENSG00000055332.15,EIF2AK2BRCAEAG2.4912e-04image4.1203e-03-0.0875image


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
ENSG00000055332.15,EIF2AK2LUADEAG9.4513e-050.17096.2216e-040.15004.2810e-030.12541.7695e-020.1043image
chr2:37100421-37104937:-LUADEER7.9586e-050.17266.0126e-040.15043.9779e-030.12651.4485e-020.1075image
ENSG00000055332.15,EIF2AK2PCPGEAG3.6428e-07-0.37632.6559e-04-0.27472.3458e-07-0.38196.2314e-03-0.2078image
chr2:37100421-37104937:-PCPGEER3.5730e-07-0.37652.5597e-04-0.27542.3962e-07-0.38176.3440e-03-0.2074image
ENSG00000055332.15,EIF2AK2SKCMEAG1.2050e-02-0.11751.3662e-05-0.20212.9481e-04-0.16881.7393e-020.1113image
chr2:37100421-37104937:-SKCMEER1.2048e-02-0.11751.3662e-05-0.20212.9480e-04-0.16881.7397e-020.1113image
ENSG00000055332.15,EIF2AK2STADEAG3.0166e-060.24037.9832e-040.17385.6687e-050.20803.0366e-050.2153image
chr2:37100421-37104937:-STADEER3.5151e-060.23881.1818e-030.16827.2862e-050.20503.0939e-050.2151image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr2:37100421-37104937:-ACCGSVA_HALLMARK_SPERMATOGENESISEER4.8243e-03-0.3429image
ENSG00000055332.15,EIF2AK2ACCGSVA_HALLMARK_SPERMATOGENESISEAG4.8243e-03-0.3429image
ENSG00000055332.15,EIF2AK2BLCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG6.1609e-130.3541image
chr2:37100421-37104937:-BLCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER6.8578e-130.3535image
ENSG00000055332.15,EIF2AK2BRCAGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG9.7700e-340.3576image
chr2:37100421-37104937:-BRCAGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER5.0676e-340.3590image
ENSG00000055332.15,EIF2AK2CESCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.9825e-150.4352image
chr2:37100421-37104937:-CESCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.7921e-150.4357image
ENSG00000055332.15,EIF2AK2CHOLGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEAG2.5488e-02-0.3827image
chr2:37100421-37104937:-CHOLGSVA_HALLMARK_IL6_JAK_STAT3_SIGNALINGEER2.5488e-02-0.3827image
chr2:37100421-37104937:-COADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.0147e-050.2622image
ENSG00000055332.15,EIF2AK2COADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.1463e-050.2607image
chr2:37100421-37104937:-DLBCGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER9.5715e-040.5482image
ENSG00000055332.15,EIF2AK2DLBCGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG1.7332e-020.4116image
chr2:37153364-37153806:-ESCAGSVA_HALLMARK_APICAL_JUNCTIONEER3.3015e-020.2262image
chr2:37100421-37104937:-ESCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.5468e-030.2475image
ENSG00000055332.15,EIF2AK2ESCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.2200e-030.2394image
chr2:37100421-37104937:-GBMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.0813e-090.4428image
ENSG00000055332.15,EIF2AK2GBMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.0813e-090.4428image
chr2:37100421-37104937:-HNSCGSVA_HALLMARK_MITOTIC_SPINDLEEER2.8326e-13-0.3234image
ENSG00000055332.15,EIF2AK2HNSCGSVA_HALLMARK_MITOTIC_SPINDLEEAG2.7888e-13-0.3235image
chr2:37100421-37104937:-KICHGSVA_HALLMARK_ANDROGEN_RESPONSEEER1.5074e-04-0.4665image
ENSG00000055332.15,EIF2AK2KICHGSVA_HALLMARK_ANDROGEN_RESPONSEEAG1.5074e-04-0.4665image
ENSG00000055332.15,EIF2AK2KIRCGSVA_HALLMARK_MITOTIC_SPINDLEEAG3.0573e-12-0.3473image
chr2:37100421-37104937:-KIRCGSVA_HALLMARK_MITOTIC_SPINDLEEER3.2975e-12-0.3468image
ENSG00000055332.15,EIF2AK2KIRPGSVA_HALLMARK_MITOTIC_SPINDLEEAG8.2086e-08-0.3187image
chr2:37100421-37104937:-KIRPGSVA_HALLMARK_MITOTIC_SPINDLEEER1.9849e-08-0.3328image
chr2:37100421-37104937:-LAMLGSVA_HALLMARK_TGF_BETA_SIGNALINGEER2.6873e-060.3724image
ENSG00000055332.15,EIF2AK2LAMLGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG3.0941e-070.4033image
ENSG00000055332.15,EIF2AK2LGGGSVA_HALLMARK_MYOGENESISEAG1.0336e-300.4732image
chr2:37100421-37104937:-LGGGSVA_HALLMARK_MYOGENESISEER1.0336e-300.4732image
chr2:37100421-37104937:-LIHCGSVA_HALLMARK_MITOTIC_SPINDLEEER2.9187e-12-0.3789image
ENSG00000055332.15,EIF2AK2LIHCGSVA_HALLMARK_MITOTIC_SPINDLEEAG2.8689e-12-0.3790image
chr2:37100421-37104937:-LUADGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER4.1546e-110.2849image
ENSG00000055332.15,EIF2AK2LUADGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG7.6954e-110.2810image
chr2:37100421-37104937:-LUSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER7.3105e-110.2865image
ENSG00000055332.15,EIF2AK2LUSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG7.3105e-110.2865image
chr2:37100421-37104937:-MESOGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEER1.0063e-030.3566image
ENSG00000055332.15,EIF2AK2MESOGSVA_HALLMARK_TNFA_SIGNALING_VIA_NFKBEAG1.0063e-030.3566image
chr2:37153364-37153806:-OVGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER1.2837e-030.3005image
ENSG00000055332.15,EIF2AK2OVGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG1.5300e-130.4144image
chr2:37100421-37104937:-OVGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER1.6312e-130.4139image
ENSG00000055332.15,EIF2AK2PAADGSVA_HALLMARK_UV_RESPONSE_DNEAG1.0872e-06-0.3578image
chr2:37100421-37104937:-PAADGSVA_HALLMARK_UV_RESPONSE_DNEER1.0872e-06-0.3578image
chr2:37100421-37104937:-PCPGGSVA_HALLMARK_UV_RESPONSE_DNEER1.6810e-10-0.4625image
ENSG00000055332.15,EIF2AK2PCPGGSVA_HALLMARK_UV_RESPONSE_DNEAG1.7987e-10-0.4619image
chr2:37100421-37104937:-PRADGSVA_HALLMARK_MITOTIC_SPINDLEEER4.2302e-15-0.3455image
ENSG00000055332.15,EIF2AK2PRADGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.6032e-14-0.3385image
ENSG00000055332.15,EIF2AK2READGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.7128e-050.4256image
chr2:37100421-37104937:-READGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.7128e-050.4256image
chr2:37100421-37104937:-SARCGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER2.0178e-090.3698image
ENSG00000055332.15,EIF2AK2SARCGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG1.4526e-090.3721image
ENSG00000055332.15,EIF2AK2SKCMGSVA_HALLMARK_MITOTIC_SPINDLEEAG4.2098e-11-0.3025image
chr2:37100421-37104937:-SKCMGSVA_HALLMARK_MITOTIC_SPINDLEEER4.2115e-11-0.3025image
chr2:37153364-37153806:-STADGSVA_HALLMARK_ANGIOGENESISEER1.3499e-030.2859image
chr2:37100421-37104937:-STADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.6600e-170.4237image
ENSG00000055332.15,EIF2AK2STADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.1171e-170.4224image
ENSG00000055332.15,EIF2AK2TGCTGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG5.7531e-080.4334image
chr2:37100421-37104937:-TGCTGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER5.7531e-080.4334image
ENSG00000055332.15,EIF2AK2THCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG3.3290e-130.3213image
chr2:37100421-37104937:-THCAGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER3.3000e-130.3213image
ENSG00000055332.15,EIF2AK2THYMGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEAG3.8478e-070.4841image
chr2:37100421-37104937:-THYMGSVA_HALLMARK_ESTROGEN_RESPONSE_LATEEER7.0864e-070.4743image
ENSG00000055332.15,EIF2AK2UCECGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG3.1119e-040.2757image
chr2:37100421-37104937:-UCECGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER4.6822e-040.2678image
chr2:37100421-37104937:-UCSGSVA_HALLMARK_DNA_REPAIREER1.0166e-040.5041image
ENSG00000055332.15,EIF2AK2UCSGSVA_HALLMARK_DNA_REPAIREAG1.1213e-040.5015image
ENSG00000055332.15,EIF2AK2UVMGSVA_HALLMARK_APICAL_SURFACEEAG1.6480e-050.5068image
chr2:37100421-37104937:-UVMGSVA_HALLMARK_APICAL_SURFACEEER1.6480e-050.5068image


Top

7. Enriched editing regions and drugs for EIF2AK2


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr2:37100421-37104937:-ACCGefitinibEER2.3698e-02-0.2782image
ENSG00000055332.15,EIF2AK2ACCGefitinibEAG2.3698e-02-0.2782image
chr2:37100421-37104937:-BLCACGP.60474EER3.9270e-15-0.3842image
ENSG00000055332.15,EIF2AK2BLCACGP.60474EAG4.5019e-15-0.3834image
ENSG00000055332.15,EIF2AK2BRCAA.770041EAG1.1725e-23-0.2995image
chr2:37100421-37104937:-BRCAA.770041EER8.0312e-24-0.3006image
ENSG00000055332.15,EIF2AK2CESCBMS.536924EAG5.9983e-16-0.4464image
chr2:37100421-37104937:-CESCBMS.536924EER8.0228e-16-0.4446image
ENSG00000055332.15,EIF2AK2CHOLAP.24534EAG6.6953e-040.5543image
chr2:37100421-37104937:-CHOLAP.24534EER6.6953e-040.5543image
ENSG00000055332.15,EIF2AK2COADMetforminEAG1.1496e-05-0.2607image
chr2:37100421-37104937:-COADMetforminEER9.9427e-06-0.2625image
chr2:37100421-37104937:-DLBCAZ628EER2.0295e-03-0.5177image
ENSG00000055332.15,EIF2AK2DLBCAZ628EAG2.6154e-02-0.3868image
ENSG00000055332.15,EIF2AK2ESCAABT.263EAG6.1504e-030.2157image
chr2:37100421-37104937:-ESCAABT.263EER5.9037e-030.2168image
chr2:37100421-37104937:-GBMBIBW2992EER8.3133e-13-0.5172image
ENSG00000055332.15,EIF2AK2GBMBIBW2992EAG8.3133e-13-0.5172image
chr2:37100421-37104937:-HNSCAZD6244EER4.2230e-17-0.3695image
ENSG00000055332.15,EIF2AK2HNSCAZD6244EAG3.9564e-17-0.3698image
chr2:37100421-37104937:-KICHJNK.Inhibitor.VIIIEER2.0890e-04-0.4576image
ENSG00000055332.15,EIF2AK2KICHJNK.Inhibitor.VIIIEAG2.0890e-04-0.4576image
ENSG00000055332.15,EIF2AK2KIRCBMS.536924EAG2.5823e-13-0.3644image
chr2:37100421-37104937:-KIRCBMS.536924EER2.3777e-13-0.3649image
chr2:37100421-37104937:-KIRPCCT007093EER8.5832e-140.4327image
ENSG00000055332.15,EIF2AK2KIRPCCT007093EAG7.9713e-120.3998image
ENSG00000055332.15,EIF2AK2LAMLCGP.60474EAG3.8264e-06-0.3671image
chr2:37100421-37104937:-LAMLCGP.60474EER9.6250e-06-0.3526image
ENSG00000055332.15,EIF2AK2LGGBAY.61.3606EAG2.7684e-360.5107image
chr2:37100421-37104937:-LGGBAY.61.3606EER2.7684e-360.5107image
ENSG00000055332.15,EIF2AK2LIHCBAY.61.3606EAG1.9469e-110.3652image
chr2:37100421-37104937:-LIHCBAY.61.3606EER1.9629e-110.3651image
chr2:37100421-37104937:-LUADA.770041EER2.0256e-15-0.3399image
ENSG00000055332.15,EIF2AK2LUADA.770041EAG3.8726e-15-0.3366image
chr2:37100421-37104937:-LUSCCEP.701EER2.7395e-09-0.2624image
ENSG00000055332.15,EIF2AK2LUSCCEP.701EAG2.7395e-09-0.2624image
chr2:37100421-37104937:-MESOBMS.536924EER7.9887e-04-0.3631image
ENSG00000055332.15,EIF2AK2MESOBMS.536924EAG7.9887e-04-0.3631image
ENSG00000055332.15,EIF2AK2OVEmbelinEAG1.4065e-090.3449image
chr2:37100421-37104937:-OVEmbelinEER2.2611e-090.3408image
chr2:37153364-37153806:-OVGW.441756EER7.0015e-03-0.2535image
chr2:37100421-37104937:-PAADATRAEER1.3025e-030.2447image
ENSG00000055332.15,EIF2AK2PAADATRAEAG1.3025e-030.2447image
ENSG00000055332.15,EIF2AK2PCPGBMS.536924EAG1.1361e-03-0.2468image
chr2:37100421-37104937:-PCPGBMS.536924EER1.0314e-03-0.2488image
chr2:37100421-37104937:-PRADBMS.509744EER2.1379e-15-0.3490image
ENSG00000055332.15,EIF2AK2PRADBAY.61.3606EAG1.3897e-140.3393image
chr2:37100421-37104937:-READBMS.536924EER8.6106e-04-0.3380image
ENSG00000055332.15,EIF2AK2READBMS.536924EAG8.6106e-04-0.3380image
chr2:37100421-37104937:-SARCAG.014699EER3.8885e-120.4229image
ENSG00000055332.15,EIF2AK2SARCAG.014699EAG4.3764e-120.4212image
ENSG00000055332.15,EIF2AK2SKCMGNF.2EAG1.3077e-15-0.3625image
chr2:37100421-37104937:-SKCMGNF.2EER1.3081e-15-0.3625image
chr2:37100421-37104937:-STADCCT007093EER1.1687e-050.2260image
ENSG00000055332.15,EIF2AK2STADCCT007093EAG1.7413e-050.2216image
ENSG00000055332.15,EIF2AK2TGCTAZD6482EAG1.5488e-100.5014image
chr2:37100421-37104937:-TGCTAZD6482EER1.5488e-100.5014image
chr2:37100421-37104937:-THCAAZD6244EER9.2973e-26-0.4513image
ENSG00000055332.15,EIF2AK2THCAAZD6244EAG8.6628e-26-0.4515image
chr2:37100421-37104937:-THYMABT.263EER4.2783e-080.5170image
ENSG00000055332.15,EIF2AK2THYMABT.263EAG2.3585e-080.5254image
ENSG00000055332.15,EIF2AK2UCECGDC.0449EAG7.0120e-08-0.4024image
chr2:37100421-37104937:-UCECGDC.0449EER2.1985e-08-0.4163image
chr2:37100421-37104937:-UCSA.770041EER1.4663e-05-0.5527image
ENSG00000055332.15,EIF2AK2UCSA.770041EAG1.6126e-05-0.5505image
ENSG00000055332.15,EIF2AK2UVMCGP.60474EAG6.9811e-08-0.6098image
chr2:37100421-37104937:-UVMCGP.60474EER6.9811e-08-0.6098image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType
chr2:37100421-37104937:-ENST00000233057.7P19525DB00328IndomethacinSmallMoleculeDrug
chr2:37100421-37104937:-ENST00000233057.7P19525DB12010FostamatinibSmallMoleculeDrug
chr2:37115110-37116083:-ENST00000233057.7P19525DB00328IndomethacinSmallMoleculeDrug
chr2:37115110-37116083:-ENST00000233057.7P19525DB12010FostamatinibSmallMoleculeDrug
chr2:37115110-37116083:-ENST00000395127.5P19525DB00328IndomethacinSmallMoleculeDrug
chr2:37115110-37116083:-ENST00000395127.5P19525DB12010FostamatinibSmallMoleculeDrug
chr2:37115110-37116083:-ENST00000405334.4P19525DB00328IndomethacinSmallMoleculeDrug
chr2:37115110-37116083:-ENST00000405334.4P19525DB12010FostamatinibSmallMoleculeDrug
chr2:37153364-37153806:-ENST00000233057.7P19525DB00328IndomethacinSmallMoleculeDrug
chr2:37153364-37153806:-ENST00000233057.7P19525DB12010FostamatinibSmallMoleculeDrug
chr2:37153364-37153806:-ENST00000395127.5P19525DB00328IndomethacinSmallMoleculeDrug
chr2:37153364-37153806:-ENST00000395127.5P19525DB12010FostamatinibSmallMoleculeDrug